. Author manuscript; available in PMC: 2016 Jun 6.

Published in final edited form as: Neurourol Urodyn. 2013 Jul 17;32(8):1096–1102. doi: 10.1002/nau.22343

TABLE I.

Patient-Oriented Outcomes

	Control		P-value	Treatment		P-value
	Pre-Rx	Post-Rx	P-value	Pre-Rx	Post-Rx	P-value
Bladder diary (episodes)	7.6 (4.2)	4.9 (3.1)	P = 0.199	6.4 (4.8)	2.5 (2.7)	P = 0.007
Pad test (g)	20.2 (24.7)	11.4 (15.5)	P = 0.225	22.2 (25.9)	9.7 (15.8)	P = 0.197
IIQ-7	27.0 (19.3)	29.2 (21.9)	P = 0.998	40.9 (22.0)	9.5 (7.2)	P = 0.0003
UDI-6	48.0 (20.4)	49.2 (21.6)	P = 0.998	48.0 (21.0)	33.2 (20.0)	P = 0.401

Mean (SD) values for the bladder diary, pad test, UDI and IIQ are presented. Rx denotes “treatment.” No significant differences in these measures were found between the groups at the start of the study (i.e., Pre-Rx). Significant differences between sessions (i.e., Pre-Rx vs. Post-Rx) were found for the bladder diary and the IIQ-7 in the treatment group only and are noted in bold.